| 篇名 |
Bisphosphonate-related osteonecrosis of the jaw: Is the medication duration related to advanced disease stage? |
| 作者 |
Yu-Pin Su, Wen-Chung Liu, Cheng-Ta Lin, Hsin-I Chien, Kuo-Chung Yang |
| 卷期/出版年月 |
57卷4期 (2024/7) |
| 頁次 |
151-156 |
| 摘要 |
Background: Osteonecrosis of the jaw (ONJ) is a serious adverse effect of therapy with bisphosphonates (BP) and other antiresorptive agents. The aim of the study was to report 13 patient cases of bisphosphonates-related osteonecrosis of the jaw (BRONJ) at Kaohsiung Veterans General Hospital (VGHKS), Taiwan, and their medical history and disease outcomes.
Materials andMethods: Thirteen symptomatic patients with BRONJ were reviewed between 1985 and 2021 at VGHKS. We included symptomatic patients who were in advanced BRONJ stages 2 and 3: 4 multiple myeloma, 3 bone metastatic breast cancer, and 6 advanced osteoporosis patients.
Results: Seven patients were American Association of Oral andMaxillofacial Surgeons’ medication-related osteonecrosis of the jaw stage 3, and 6were stage 2. The average antiresorptive medication duration was 25.83 ± 31.45months inBRONJ stage 2 patients and 53.71 ± 31.25months in BRONJ stage 3 patients, respectively. No correlation was found between the antiresorptive agent duration and BRONJ stage (P = 0.098; Mann-Whitney U test) among cancer (P = 0.157; Mann-Whitney U test) and osteoporosis patients (P = 0.184; Mann-Whitney U test).
Conclusions: Most of them died of terminal stage cancer disease or complications of being bedridden. The correlation between the duration of antiresorptive agents and BRONJ stage needs larger patient data to confirm the result. |
| 關鍵詞 |
Bisphosphonates; Antiresorptive agents; Medication-related osteonecrosis of the jaw |
| 分類 |
Original Article |
